Torley Helen 4
4 · HALOZYME THERAPEUTICS, INC. · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Halozyme (HALO) CEO Helen Torley Exercises Options, Sells Shares
What Happened
Helen Torley, President & CEO and a director of Halozyme Therapeutics (HALO), exercised 50,000 stock options (20,000 on 6/1, 20,000 on 6/2, 10,000 on 6/3) at an exercise price of $12.07 per share (exercise cost ≈ $603,500). She sold the 50,000 resulting shares in open-market transactions across June 1–3, 2026 for total gross proceeds of approximately $3,370,008 (weighted average sale price ≈ $67.40). Net proceeds after exercise costs were roughly $2.77M. The exercises and sales were reported on a Form 4 filed June 3, 2026.
Key Details
- Transaction types: M = option exercise; S = open-market sale. The filing also shows corresponding derivative disposition lines reflecting conversion of options to shares.
- Exercise price: $12.07 per share; total exercised: 50,000 shares; total exercise cost ≈ $603,500.
- Sales: 50,000 shares sold across 6/1–6/3; gross proceeds ≈ $3,370,008; weighted avg sale price ≈ $67.40/share.
- Dates: June 1, 2026; June 2, 2026; June 3, 2026. Form 4 filed June 3, 2026.
- Footnotes: F1 — sales were made pursuant to a written 10b5-1 trading plan adopted March 21, 2025; sales represent shares acquired upon exercise of ten-year options (expiring Feb 2027). F11 — the options were originally granted Feb 22, 2017. Footnotes F2–F10 detail the price ranges for grouped sales and can be requested for per-price breakdowns.
- Shares owned after the transactions: not specified in the provided filing details.
Context
These transactions reflect an exercise of long-dated options followed by an immediate sale of the acquired shares under a pre-established 10b5-1 plan (effectively a cashless exercise + sell). Such transactions are commonly used by insiders for liquidity and tax management and are not, by themselves, proof of a change in view on the company’s prospects.
Insider Transaction Report
Form 4
Torley Helen
DirectorPRESIDENT AND CEO
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-01$12.07/sh+20,000$241,400→ 787,780 total - Sale
Common Stock
[F1][F2]2026-06-01$66.39/sh−1,610$106,885→ 786,170 total - Sale
Common Stock
[F1][F3]2026-06-01$67.41/sh−12,989$875,588→ 773,181 total - Sale
Common Stock
[F1][F4]2026-06-01$68.35/sh−5,401$369,137→ 767,780 total - Exercise/Conversion
Common Stock
[F1]2026-06-02$12.07/sh+20,000$241,400→ 787,780 total - Sale
Common Stock
[F1][F5]2026-06-02$66.31/sh−16,600$1,100,812→ 771,180 total - Sale
Common Stock
[F1][F6]2026-06-02$66.75/sh−3,400$226,933→ 767,780 total - Exercise/Conversion
Common Stock
[F1]2026-06-03$12.07/sh+10,000$120,700→ 777,780 total - Sale
Common Stock
[F1][F7]2026-06-03$66.37/sh−400$26,547→ 777,380 total - Sale
Common Stock
[F1][F8]2026-06-03$67.67/sh−1,500$101,513→ 775,880 total - Sale
Common Stock
[F1][F9]2026-06-03$68.74/sh−2,000$137,472→ 773,880 total - Sale
Common Stock
[F1][F10]2026-06-03$69.69/sh−6,100$425,121→ 767,780 total - Exercise/Conversion
Option to Purchase Common Stock
[F1][F11]2026-06-01$12.07/sh−20,000$241,400→ 31,923 totalExercise: $12.07Exp: 2027-02-22→ Common Stock (20,000 underlying) - Exercise/Conversion
Option to Purchase Common Stock
[F1][F11]2026-06-02$12.07/sh−20,000$241,400→ 11,923 totalExercise: $12.07Exp: 2027-02-22→ Common Stock (20,000 underlying) - Exercise/Conversion
Option to Purchase Common Stock
[F1][F11]2026-06-03$12.07/sh−10,000$120,700→ 1,923 totalExercise: $12.07Exp: 2027-02-22→ Common Stock (10,000 underlying)
Footnotes (11)
- [F1]The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
- [F10]Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.120 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F11]Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.
- [F2]Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.840 to $66.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.840 to $67.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.840 to $68.820. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.630 to $66.625. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.630 to $67.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F7]Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.000 to $66.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F8]Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.090 to $68.000. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F9]Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Signature
/s/ James R. Oehler, Attorney-in-Fact|2026-06-03